Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06384820

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma Clinical Trial

Official title:
A Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Clinical Trial Summary

This study is researching an investigational drug called REGN2810, also known as cemiplimab, when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC). The aim of the study is to see if cemiplimab or cemiplimab in combination with fianlimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery. The study is looking at several other research questions, including: - Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make it possible to have a less extensive surgery or a different treatment plan after surgery - Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make the cancer less likely to come back after surgery - What side effects may happen from taking the cemiplimab or cemiplimab in combination with fianlimab - How much of the cemiplimab or cemiplimab in combination with fianlimab is in the blood at different times - Whether the body makes antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06384820
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email clinicaltrials@regeneron.com
Status Not yet recruiting
Phase Phase 2
Start date November 14, 2024
Completion date May 6, 2030
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05377905 - Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) Phase 1/Phase 2
Recruiting NCT05888844 - A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04050436 - Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Phase 2
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Completed NCT04616196 - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Phase 1/Phase 2
Recruiting NCT05108090 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04975152 - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Phase 1
Completed NCT01500954 - Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma N/A
Suspended NCT04916002 - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Phase 2
Recruiting NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Recruiting NCT04664582 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Terminated NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy Phase 1
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Recruiting NCT05878288 - Deep sequencIng in Cutaneous Squamous CEll caRciNomas Phase 2